The 2-day program at the Gaylord Opryland Resort will bring together established and emerging eye care leaders for sessions on leadership development, artificial intelligence, inclusion, and career growth.
|Videos|August 25, 2021
RVL Pharmaceuticals: Shifting toward ocular aesthetics
Author(s)David Hutton, Alex Delaney-Gesing
COO JD Schaub provides an overview of how RVL Pharmaceuticals has shifted toward becoming an ocular aesthetics company, with the sole purpose to fully focus on UPNEEQ®.
Advertisement
JD Schaub, chief operating officer at RVL Pharmaceuticals, provides an overview of how the company has shifted toward focusing on ocular aesthetics, along with the sole purpose to fully focus on UPNEEQ®, a prescription eye drop.
Advertisement
Related to this article
Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Two investigational pipeline therapies take aim at the root causes of dry eye disease
Dry eye care pivots to root-cause diagnosis and personalized biologics/devices,
Cataract surgery becomes refractive: learn how IOL choices and preop counseling across distance, intermediate and near turn 20/20 into 20/happy.
Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Alvotech files first known aflibercept 8 mg biosimilar with EMA
2
AAO 2026: How to become an ocular pain detective in dry eye
3
AAO 2026: Tinlarebant in Stargardt disease: Jacque Duncan, MD, on DRAGON results
4
AAO 2026: Vamikibart shows sustained gains in uveitic macular edema as FDA accepts BLA
5